Skip to main content

Leading minimally-invasive technologies for diagnosing and treating a variety of heart and vascular conditions

Getting WATCHMAN During COVID-19​
We’re committed to advancing cardiology through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.

Delivering Meaningful Innovation

A Pioneering Alternative to Blood Thinners. The WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage – the area of the heart where stroke-causing blood clots commonly form in NVAF. This technology, which is built upon the most studied and implanted LAAC device in the world, features a new, fully rounded design that offers physicians the ability to safely enter, and maneuver within, the left atrial appendage.

Designed to Optimize TAVR. The SENTINEL™ Cerebral Protection System (CPS) is the first and only commercially available device in the U.S. offering protected TAVR – proven embolic protection against the risk of TAVR-related stroke.

Healing with Confidence. The SYNERGY™ Bioabsorbable Polymer Stent System is the first and only FDA-approved stent with a fast-absorbing bioabsorbable polymer coating to enable rapid healing and provide freedom from long-term polymer exposure.

Conditions We Treat

  • Cardiovascular Diseases
  • Coronary Artery Disease
  • Acute Myocardial Infarction

Solutions We Offer

Structural Heart

  • Left Atrial Appendage Closure (LAAC)
  • Transcatheter Aortic Valve Replacement (TAVR)
  • Cerebral Embolic Protection (CEP)

Coronary Therapies

  • Drug-Eluting Stents
  • Intravascular Ultrasound (IVUS)
  • Fractional Flow Reserve (FFR)
  • Atherectomy
  • Bare-Metal Stents
  • Catheters
  • Balloons
  • Guide Wires
  • Thrombectomy


1. Arora S, et al. "Transcatheter Aortic Valve Replacement: Comprehensive Review and Present Status." Tex Heart Inst J. 2017; 44(1):29-38.

2. CHD Source: Hurst’s the Heart, edition 12e. MI Source: AHA Heart Disease & Stroke Statistics, 2010 Update

3. Boston Scientific – Internal data